Registered title, quoted from ClinicalTrials.gov
Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS)
An open trial on amyotrophic lateral sclerosis, registered on ClinicalTrials.gov. Led by Shanghai East Hospital, Tongji University; 1 other hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page
- Study siteEast Hospital上海市东方医院ShanghaiHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06765564, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 60 years; sex: all
Registered eligibility fields
Poorly controlled hypertension, with systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg after treatment.
Exclusion criterion 18
Patients with elevated liver function test results during the screening period, such as total bilirubin >1.5 times the upper limit of normal (ULN), or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times ULN.
Exclusion criterion 12
Patients who have abnormal kidney function test results during the screening period, such as serum creatinine >1.5 mg/dL or an estimated creatinine clearance rate <60 mL/min calculated by the Cockcroft and Gault formula.
Exclusion criterion 13
Coagulation abnormalities (prothrombin time [PT] or international normalized ratio [INR] >1.5 times ULN; activated partial thromboplastin time [APTT] >1.5 times ULN) or those currently receiving anticoagulation therapy.
Exclusion criterion 17
Patients with hepatitis A, active hepatitis B (HBsAg positive and HBV DNA ≥500 IU/ml, excluding drug- or other-caused hepatitis), active hepatitis C (anti-HCV antibody positive and HCV RNA positive), hepatitis E, human immunodeficiency virus (HIV) antibody positive, or syphilis treponemal antibody positive.
Exclusion criterion 15
Pregnant or breastfeeding women.
Exclusion criterion 21
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06765564, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients themselves or their legal guardians must consent to undergo this treatment protocol and sign the Informed Consent Form (ICF).
- Age between 18 and 60 years, inclusive, with no gender restrictions.
- Diagnosed with ALS according to the World Federation of Neurology criteria, and the initial diagnosis date is between 6 to 24 months before the screening date.
- Patients who have received standard treatment in the past with poor efficacy or disease progression.
- Forced Vital Capacity (FVC) should be ≥50%.
- During any night of the screening period, the total time with peripheral blood oxygen saturation <90% should not exceed 2%.
- Patients should be deemed by the investigator to be in good nutritional status, with a Body Mass Index (BMI) ≥18.5.
- Male patients and their spouses, as well as women of childbearing age, should agree to implement effective contraceptive measures from the time of signing the ICF until one year after the start of treatment.
- Patients should be able to cooperate in the collection and preservation of medical history data and the visit process.
Exclusion Criteria:
- Patients with symptoms of neuromuscular weakness but cannot be conclusively determined to have ALS.
- Patients diagnosed with severe cognitive impairment, clinical dementia, or major psychiatric disorders, including but not limited to schizophrenia, bipolar disorder, or severe depression, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
- Patients with any disease that impairs nerve or muscle function, such as peripheral neuropathy or metabolic myopathy.
- Patients with a history of malignant tumors or a previous diagnosis of malignancy.
- Within the two weeks preceding the screening period, patients who experienced acute active infections requiring treatment with antibiotics, antiviral drugs, or antifungal medications.
- ALS patients with concomitant respiratory failure.
- Patients who have previously undergone any allogeneic cell therapy or organ transplantation.
- Patients who have Participated in other clinical trials within the three months prior to screening.
- Patients with a history of tracheostomy or those using mechanical ventilatory support.
- Patients with a documented history of severe allergic reactions to general anesthesia drugs or previous severe allergic reactions for other reasons.
- Patients with intracranial organic diseases causing increased intracranial pressure.
- Patients with elevated liver function test results during the screening period, such as total bilirubin >1.5 times the upper limit of normal (ULN), or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times ULN.
- Patients who have abnormal kidney function test results during the screening period, such as serum creatinine >1.5 mg/dL or an estimated creatinine clearance rate <60 mL/min calculated by the Cockcroft and Gault formula.
- Other clinically significant laboratory abnormalities during the screening period.
- Patients with hepatitis A, active hepatitis B (HBsAg positive and HBV DNA ≥500 IU/ml, excluding drug- or other-caused hepatitis), active hepatitis C (anti-HCV antibody positive and HCV RNA positive), hepatitis E, human immunodeficiency virus (HIV) antibody positive, or syphilis treponemal antibody positive.
- Patients with impaired consciousness.
- Coagulation abnormalities (prothrombin time [PT] or international normalized ratio [INR] >1.5 times ULN; activated partial thromboplastin time [APTT] >1.5 times ULN) or those currently receiving anticoagulation therapy.
- Poorly controlled hypertension, with systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg after treatment.
- Severe diabetes with late complications; patients with other diseases affecting limb mobility (e.g., limping, osteoarthritis, rheumatoid arthritis, gout, etc.).
- Patients who have undergone surgery or experienced trauma (including fractures) in the past month.
- Pregnant or breastfeeding women.
- Patients who, in the opinion of the investigator, have poorly controlled systemic diseases or other conditions that make them unsuitable for participation in this clinical study.
Quoted from ClinicalTrials.gov, NCT06765564, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06765564, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.